Celcuity (NASDAQ:CELC) Given New $115.00 Price Target at Stifel Nicolaus

Celcuity (NASDAQ:CELC) had its target price raised by Stifel Nicolaus from $68.00 to $115.00 in a report published on Thursday morning,Benzinga reports. Stifel Nicolaus currently has a buy rating on the stock.

Other equities analysts have also recently issued reports about the company. Needham & Company LLC set a $95.00 target price on Celcuity in a report on Monday, October 20th. HC Wainwright increased their price objective on shares of Celcuity from $66.00 to $77.00 and gave the company a “buy” rating in a report on Wednesday, October 22nd. Leerink Partners lifted their price objective on Celcuity from $28.00 to $60.00 and gave the stock an “outperform” rating in a research note on Monday, July 28th. Wall Street Zen cut shares of Celcuity from a “hold” rating to a “sell” rating in a research report on Sunday, October 26th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Celcuity in a report on Wednesday, October 8th. Six equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Celcuity has a consensus rating of “Moderate Buy” and a consensus price target of $91.00.

Celcuity Stock Up 7.8%

Celcuity stock traded up $6.68 during mid-day trading on Thursday, reaching $92.68. The stock had a trading volume of 1,311,863 shares, compared to its average volume of 730,620. Celcuity has a one year low of $7.57 and a one year high of $94.06. The company has a 50-day moving average price of $61.61 and a two-hundred day moving average price of $36.77. The company has a market capitalization of $3.93 billion, a price-to-earnings ratio of -25.25 and a beta of 0.72. The company has a debt-to-equity ratio of 2.24, a current ratio of 4.58 and a quick ratio of 4.58.

Celcuity (NASDAQ:CELC) last issued its earnings results on Wednesday, November 12th. The company reported ($0.92) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.05) by $0.13. The firm had revenue of $0.15 million during the quarter. On average, analysts expect that Celcuity will post -2.62 EPS for the current fiscal year.

Hedge Funds Weigh In On Celcuity

Institutional investors have recently bought and sold shares of the business. US Bancorp DE grew its holdings in Celcuity by 25.4% in the 3rd quarter. US Bancorp DE now owns 706 shares of the company’s stock valued at $35,000 after buying an additional 143 shares in the last quarter. Rhumbline Advisers increased its position in shares of Celcuity by 1.2% during the second quarter. Rhumbline Advisers now owns 42,697 shares of the company’s stock valued at $570,000 after acquiring an additional 503 shares during the last quarter. Ogorek Anthony Joseph NY ADV purchased a new position in shares of Celcuity during the 3rd quarter worth approximately $27,000. Intech Investment Management LLC increased its holdings in Celcuity by 5.2% in the 2nd quarter. Intech Investment Management LLC now owns 14,855 shares of the company’s stock valued at $198,000 after purchasing an additional 734 shares during the last quarter. Finally, BNP Paribas Financial Markets grew its stake in shares of Celcuity by 78.9% in the second quarter. BNP Paribas Financial Markets now owns 2,647 shares of the company’s stock valued at $35,000 after buying an additional 1,167 shares in the last quarter. 63.33% of the stock is owned by hedge funds and other institutional investors.

About Celcuity

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.